Analysts’ Recommendations for Eli Lilly in March 2018



Analysts’ estimates

As we discussed earlier, Eli Lilly and Company (LLY) surpassed Wall Street analysts’ estimates for EPS (earnings per share) and revenue in 4Q17. It reported EPS of $1.14 on revenue of ~$6.2 billion compared to its estimated EPS of $1.07 on revenue of ~$5.9 billion in the quarter.

Eli Lilly also surpassed analysts’ estimates for EPS and revenue for 2017, reporting EPS of $4.28 on revenue of ~$22.9 billion compared to the estimate of $4.22 on revenue of ~$22.7 billion for the year.

The chart above shows analysts’ recommendations for Eli Lilly over the last 12 months. In 1Q18, Wall Street analysts expect EPS of $1.14 on revenue of $5.5 billion for the company, a ~5.0% rise compared to 1Q17.

Article continues below advertisement

Analysts’ recommendations

Eli Lilly’s stock price has fallen nearly 11.2% in the last 12 months and nearly 11.5% in 2018 year-to-date. Analysts expect the stock to rise ~21.5% over the next 12 months. Their recommendations show a 12-month target price of $90.80 per share compared to LLY’s price of $74.76 per share on March 23, 2018.

As of March 26, 2018, there are 22 analysts tracking Eli Lilly stock. Of these, 13 have recommended “buys,” seven have recommended “holds,” and two have recommended “sells” on the stock. The consensus rating for Eli Lilly stands at 2.23, which represents a “buy” for long-term and value investors. Changes in analysts’ recommendations and estimates for target price are based on changes in the trends of a stock’s price and on developments and changes in a company’s performance.

The PowerShares Dynamic Pharmaceuticals ETF (PJP) holds 5.1% of its total investments in Eli Lilly, 5.0% in Bristol-Myers Squibb (BMY), 4.3% in AbbVie (ABBV), and 5.0% in Amgen (AMGN).


More From Market Realist